MARKET

NVRO

NVRO

Nevro
NYSE

Real-time Quotes | Nasdaq Last Sale

123.78
-0.42
-0.34%
After Hours: 123.78 0 0.00% 16:06 09/21 EDT
OPEN
124.68
PREV CLOSE
124.20
HIGH
126.36
LOW
123.42
VOLUME
340.02K
TURNOVER
--
52 WEEK HIGH
188.14
52 WEEK LOW
99.54
MARKET CAP
4.32B
P/E (TTM)
-62.8006
1D
5D
1M
3M
1Y
5Y
Baxter, Medtronic among MedTech favorites at BofA despite COVID-19 impact
Noting signs of weaker procedure volumes in Q3 2021 revealed at a recent healthcare conference, Bank of America urges investors to ignore the COVID-19 impact and make investment decisions on MedTech stocks
Seekingalpha · 09/13 17:55
Alger Weatherbie Specialized Growth Portfolio Buys Apria Inc, Latham Group Inc, Ollie's Bargain ...
GuruFocus News · 09/07 23:38
Why Is Nevro (NVRO) Up 8.6% Since Last Earnings Report?
Zacks.com · 09/03 15:31
Nevro to Present at Baird 2021 Global Healthcare Conference
Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that D. Keith Grossman, Nevro's Chairman, CEO and President, will present at the Baird 2021 ...
PR Newswire · 08/26 10:00
Nevro to Present at Morgan Stanley 19th Annual Global Healthcare Conference
Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that D. Keith Grossman, Nevro's Chairman, CEO and President, will present at the Morgan Stan...
PR Newswire · 08/25 10:00
Bridger Management, Llc Buys Centene Corp, Nevro Corp, Post Holdings Partnering Corp, Sells HCA ...
GuruFocus News · 08/24 18:38
Nevro to Present at Wells Fargo Virtual Healthcare Conference
/PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that D. , Nevro's Chairman, CEO and President, will present at the Wells Far...
PR Newswire - PRF · 08/23 10:00
Looking into Nevro's Return on Capital Employed
After pulling data from Benzinga Pro it seems like during Q2, Nevro's (NYSE:NVRO) reported sales totaled $102.33 million. Despite a 29.98% in earnings, the company posted a loss of $15.76 million.
Benzinga · 08/20 18:02
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of NVRO. Analyze the recent business situations of Nevro through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 16 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average NVRO stock price target is 138.15 with a high estimate of 165.00 and a low estimate of 112.00.
EPS
Institutional Holdings
Institutions: 294
Institutional Holdings: 44.68M
% Owned: 128.16%
Shares Outstanding: 34.87M
TypeInstitutionsShares
Increased
74
2.47M
New
39
954.08K
Decreased
62
1.41M
Sold Out
35
1.03M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
+0.10%
Healthcare Equipment & Supplies
+0.22%
Key Executives
Chairman/President/Chief Executive Officer/Director
D. Keith Grossman
Chief Financial Officer
Roderick MacLeod
Chief Human Resource Officer
Lori Ciano
Vice President
Christopher Christoforou
Vice President
Donald Middlebrook
General Counsel/Secretary
Kashif Rashid
Other
David Caraway
Other
Niamh Pellegrini
Lead Director/Independent Director
Michael DeMane
Director
Sridhar Kosaraju
Independent Director
Frank Fischer
Independent Director
Shawn McCormick
Independent Director
Kevin O'Boyle
Independent Director
Karen Prange
Independent Director
Susan Siegel
Independent Director
Brad Vale
Independent Director
Elizabeth Weatherman
No Data
About NVRO
Nevro Corp. is a global medical device company that provides solutions for the treatment of chronic pain. The Company has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain, with the Senza Omnia platform. Its Senza System, Senza II System, and the Senza Omnia System are the SCS systems that delivers Nevro's 10 kilohertz (kHz) therapy. The Senza system is focused on creating traditional low frequency electrical impulses and its HF10 therapy, which allows for pain relief without paresthesia. Its HF10 therapy is designed to deliver neuromodulation solutions for treating chronic pain. The HF10 therapy delivers waveforms at 10,000 Hertz (Hz) pulse rate with a statistically driven and clinically verified programming algorithm.

Webull offers kinds of Nevro Corp stock information, including NYSE:NVRO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NVRO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NVRO stock methods without spending real money on the virtual paper trading platform.